The NCPE recommends reimbursement of alemtuzumab (Lemtrada®).

The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.

The NCPE considers dabrafenib (Tafinlar®) to be cost effective compared to vemurafenib.

The NCPE does not recommend regorafenib (Stivarga®) as a cost-effective treatment option.

The NCPE does not consider Suboxone® to be cost-effective compared to methadone for the treatment of opioid dependence.

The NCPE does not recommend reimbursement of teriflunomide
(Aubagio®) at the current price.

The NCPE believe that, at the submitted price, brentuximab is not cost effective for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin Lymphoma who have failed at least one autologous stem cell transplant

The NCPE believe that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel

The NCPE consider this to be a cost effective product for the defined patient population in combination with psychosocial intervention.

The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost effective for the treatment of metastatic castration resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated